Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Alibaba

Equifax

Illumina

Generation Investment Management, the firm co-founded by Al Gore (Trades, Portfolio) and David Blood, disclosed this month that its top four buys during the fourth quarter of 2020 included a new position in Alibaba Group Holding Ltd. (NYSE:BABA) and boosts to its Equifax Inc. (NYSE:EFX), Baxter International Inc. (NYSE:BAX) and Illumina Inc. (NASDAQ:ILMN) holdings.

Top 4 4th-Quarter Buys of Al Gore's Generation Investment Management

Baxter is a moat-worthy healthcare innovation company and ended 2020 with revenue growth. Its shares are still down from a year ago, and I see it as being a solid recovery play.

Why It's Time To Rotate Back To Baxter International

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter's Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L. Stroucken, former executive chairman and ch

Baxter Appoints Dr. David Wilkes to Its Board and Albert Stroucken as Lead Independent Director

Bristol-Myers

Cigna

Cisco Systems

Chevron

Barrick Gold

Home Depot

Johnson & Johnson

McDonald's

Mondelez

Merck

Procter & Gamble

Raytheon Technologies

UnitedHealth Group

Exxon Mobil

31 Of 50 Stocks Billionaires Best Love Pay Dividends As Of February

Baxter International's (BAX) CEO Jose Almeida on Q4 2020 Results - Earnings Call Transcript

Baxter (BAX) delivered earnings and revenue surprises of 5.26% and 0.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Q4 Earnings and Revenues Surpass Estimates

Shares of Baxter International (NYSE:BAX) moved higher by 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 1700.00% over the past year to $0.80, which beat the estimate of $0.76.

Recap: Baxter International Q4 Earnings

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended December 31, 2020, and provided its financial guidance for 2021. “Amid an unprecedented global public health crisis, Baxter remains focused on advancing our Mission for patients and driving value for all stakeholders,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “Our 2020 performance

Baxter Reports Fourth-Quarter and Full-Year 2020 Results

Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 25, 2021. About Baxter Every day, millions of patients and

Baxter to Present at SVB Leerink 10th Annual Global Healthcare Conference

Boston Scientific

Medtronic

Stryker

Thermo Fisher Scientific

The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.

This Medical Device Maker Will Be Well Positioned Post COVID

Agilent Technologies

Centene

Veeva Systems

Walgreens

According to the GuruFocus All-in-One Screener as of Jan. 15, the following Health Care stocks are popular among gurus.

5 Health Care Stocks Gurus Are Buying

We think that Baxter International currently is a better pick compared to Boston Scientific. BAX stock trades at about 3.6x trailing Revenues, compared to around 5.2x for Boston Scientific.

Baxter Is A Better Choice Than Boston Scientific Stock

Novavax

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter BioPharma Solutions announced an agreement with Novavax to provide sterile manufacturing services for its COVID-19 vaccine candidate.

Baxter Biopharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/5044187 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Bax

Baxter to Host Fourth-Quarter 2020 Financial Results Conference Call for Investors

We believe that Baxter stock, a healthcare supply company, is a good buying opportunity at the present time. BAX stock trades near $80 currently and it is, in fact, down 16% from its pre-Covid high of $93 in February 2020 – just before the coronavirus pandemic hit the world.

Baxter Stock Can Offer 15% Upside

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. José (Joe) E. Almeida, Baxter's chairman and chief executive officer, is scheduled to present on Monday, January 11, 2021 at 9:10 a.m. Eastern Time. The live webcast of Baxter's presentation, along with accompanying slides, can be accessed at www.baxter.com and will be available for replay through Februa

Baxter to Present at the 39th Annual J.P. Morgan Healthcare Conference

Baxter's (BAX) Vital Edge program enables AdventHealth Tampa to achieve cost savings.

Baxter's (BAX) Vital Edge Program Aids Patient Blood Management

TAMPA, Fla.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, and AdventHealth Tampa today announced that AdventHealth Tampa will realize approximately $200,000 in annual savings through its involvement in Baxter's Vital Edge program. Vital Edge is a data-driven, evidence-based intraoperative hemostasis management program designed to help hospitals and health care providers improve hemostasis utilization practices impacting three interconn

Baxter and AdventHealth Tampa Announce Cost Savings Achieved Through Intraoperative Hemostasis Management Program

Automatic Data Processing

Intercontinental Exchange

Reckitt Benckiser Group PLC

The MS Global Franchise Fund (Trades, Portfolio), which is part of investment bank Morgan Stanley (NYSE:MS), disclosed its third-quarter portfolio earlier this week.

The Top 5 Trades of the MS Global Franchise Fund

Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.

Baxter (BAX) Announces Site Expansion to Improve Patient Care

Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.

Baxter (BAX) Gets FDA Nod for Homechoice Claria APD System

BAX offers a broad portfolio of essential, life-saving healthcare products to treat acute and chronic illnesses. There is no other competitor in the space that competes with BAX in all of their businesses.

Baxter Is Poised For A Breakout Given Strong Fundamentals And An Aging Population

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of the Homechoice Claria automated peritoneal dialysis (APD) system with Sharesource connectivity platform. Homechoice Claria combines a simple user interface with the benefits of Sharesource, the only two-way remote patient management platform for patients on peritoneal dialysis in the U.S. Homechoice Claria is cleared for b

Baxter Announces U.S. FDA 510(k) Clearance of Homechoice Claria with Sharesource

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 3rd Annual HealthCONx virtual conference via webcast on Tuesday, December 1, 2020. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 11:20 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 30, 2021. About Baxter Every day, millions of pa

News for Baxter Stock (BAX)